Core Insights - The updated NCCN Guidelines now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in cancer patients, reflecting a consensus among key health organizations [1][6] - New research highlights the significant impact of COVID-19 on cancer patients, including increased hospitalization rates and treatment disruptions [2][3][6] Group 1: NCCN Guidelines and Monoclonal Antibodies - The NCCN Guidelines advise the use of available monoclonal antibodies for COVID-19 prevention in immunocompromised individuals, emphasizing the importance of tailored approaches to treatment [1][4][6] - Mark Wingertzahn, Ph.D., from Invivyd, stated that monoclonal antibodies are transformative in providing targeted protection and reducing severe illness risks for cancer patients [4][6] Group 2: Research Findings on Cancer Patients and COVID-19 - The NCCAPS study followed 1,572 cancer patients with COVID-19, revealing high hospitalization rates and treatment delays, particularly among those undergoing chemotherapy [3][6] - Over 50% of cancer treatment disruptions were attributed to COVID-19, raising concerns about continuity of care and long-term patient outcomes [3][6]